Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DO78YZ
|
|||
| Drug Name |
GMA105
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Obesity [ICD-11: 5B81; ICD-10: E66] | Phase 3 | [1] | |
| Type-2 diabetes [ICD-11: 5A11] | Phase 3 | [1] | ||
| Company |
Gmax Biopharm
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glucagon-like peptide 1 receptor (GLP1R) | Target Info | Inhibitor | [1] |
| KEGG Pathway | cAMP signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Insulin secretion | ||||
| Reactome | Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | |||
| G alpha (s) signalling events | ||||
| Glucagon-type ligand receptors | ||||
| WikiPathways | GPCRs, Class B Secretin-like | |||
| Integration of energy metabolism | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Gmax Biopharm. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.